RASP Stock Overview
Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Actavia Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0078 |
| 52 Week High | US$0.032 |
| 52 Week Low | US$0.0062 |
| Beta | -61.45 |
| 1 Month Change | 1.30% |
| 3 Month Change | n/a |
| 1 Year Change | 36.84% |
| 3 Year Change | -84.40% |
| 5 Year Change | -94.80% |
| Change since IPO | -99.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| RASP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -4.7% | -3.7% |
| 1Y | 36.8% | -2.7% | 20.2% |
Return vs Industry: RASP exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: RASP exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| RASP volatility | |
|---|---|
| RASP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RASP's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine RASP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 1 | n/a | www.rasna.com |
Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. It is developing RASP-201, a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase, a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301, an NCE for NPM1, currently at the pre-clinical stage to treat refractory AML with reduced toxicity. The company was formerly known as Rasna Therapeutics, Inc. and changed its name to Actavia Life Sciences, Inc. in October 2023.
Actavia Life Sciences, Inc. Fundamentals Summary
| RASP fundamental statistics | |
|---|---|
| Market cap | US$6.02m |
| Earnings (TTM) | -US$4.44m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs RASP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RASP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.44m |
| Earnings | -US$4.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0058 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -10.7% |
How did RASP perform over the long term?
See historical performance and comparison